Evidence for Dry Eye Treatment in Hematopoietic Stem Cells Post-Transplantation

Authors

  • Isabelle Campos de Azevedo Federal University of Rio Grande do Norte
  • Jéssica Naiara de Medeiros Araújo
  • Isabelle Katherinne Fernandes Costa
  • Alexsandra Rodrigues Feijão
  • Rita de Cássia Lira da Silva
  • Jéssica de Araújo Olímpio
  • Priscila Fernandes Meireles Câmara
  • Hanna Priscila da Silva
  • Jéssica Valeska Herculano Lima
  • Danielly Oliveira Pitombeira
  • Allyne Fortes Vitor
  • Marcos Antonio Ferreira Júnior

DOI:

https://doi.org/10.3823/1924

Keywords:

Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Graft vs. host disease, Keratoconjunctivitis Sicca, Dry Eye Syndromes

Abstract

Introduction: Hematopoietic Stem Cell Transplantation (HSCT) is a treatment modality for oncology and hematological diseases genetically inherited or acquired. The morbidities and mortalities related to HSCT are evident in its different phases, such as the Graft Versus Host Disease especially on dry eye syndrome, one of the most complication of chronic phase, characterized as a multifactorial disease of the ocular surface. Several treatments may be directed to the dry eye and the consequences caused by it during the HSCT post-period.

Objective: To reveal the treatments for dry eye in patients after HSCT period.

Method: This is a literature integrative review performed by the SCOPUS databases, National Library of Medicine (PubMed); Web of Science and Cumulative Index to Nursing and Allied Heath Literature (CINAHL).

Results: Of the 1,551 articles identified, there were 21 in the final sample. Regarding the treatments addressed, the most often used was found the cyclosporine 0.05%, followed by allogeneic and autologous drops.

Conclusion: There was no consensus identified as the best type of treatment for these patients. However, it is known that depend mainly on clinical features of chronic graft-versus-host eye on the post-transplantation situation.

Author Biography

Isabelle Campos de Azevedo, Federal University of Rio Grande do Norte

Nurse. Master's Student in Post-Graduate Program in Nursing of the Federal University of Rio Grande do Norte. Natal/RN, Brazil.

References

Voltarelli JC, Pasquini R, Ortega ETT. Transplante de células-tronco hematopoéticas. São Paulo: Atheneu; 2009. 1280p.

Santos CLT, Sawada NO, Santos JLF. Evaluation of the health-related quality of life of hematopoietic stem cell transplantation patients. Rev Latino-Am Enfermagem. 2011; 19(6): 1322-8.

Ministério da Saúde (BR). Portaria Nº 931 de 2 de maio de 2006. Aprova o Regulamento Técnico para Transplante de Células-Tronco Hematopoéticas. Brasília: Ministério da Saúde; 2006. 16p.

Azevedo W. Doença enxerto versus hospedeiro aguda A-GVHD. Rev Bras Hematol Hemoter. 2010; 32(Supl. 1): 16-21.

Yamane M, Ogawa Y, Fukui M, Kamoi M, Saijo-Ban Y, Yaguchi S. et al. Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye. Optom Vis Sci. 2015; 92(4): 25-32.

Ogawa Y, Dogru M, Uchino M, Tatematsu Y, Kamoi m, Yamamoto Y. et al. Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. Bone Marrow Transplant. 2010; 45: 565-9.

Fonseca EC, Arruda GV, Rocha EM. Olho seco: etiopatogenia e tratamento. Arq Bras Oftalmol. 2010; 73(2): 197-203.

França CFSM, Fernandes APNL, Carvalho DPSRP, Xavier SSM, Ferreira Junior MA, Botarelli FR, et al. Evidence of interventions for the risk of dry eye in critically ill patients: an integrative review. Applied Nursing Research. 2016; 29: 14-7.

Broome ME. Integrative literature reviews for the development of concepts. In Rodgers BL, Knafl KA. Editors. Concept Development in Nursing. W.B. Saunders Co., Philadelphia, PA.1993; pp. 231-50.

Whittemore R, Knafl K. The integrative review: updated methodology Methodological issues in nursing research. J Adv Nurs. 2005; 52(5): 546-53.

Kitchenham, B. Procedures for performing systematic review. Software Engineering Group, Department of Computer Science, Keele University, Keele (UK); 2004.

Ham W, Jordan P. Systematic review as a research method in postgraduate nursing education. Health SA Gesondheid. 2015; (20).

Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: elaboração de revisão sistemática e metanálise de ensaios clínicos randomizados. Brasília: Ministério da Saúde; 2012.

Melnyk BM, Fineout-Overholt E, Stillwell SB, Williamson KM. Evidence-based practice: step by step. Am J Nurs. 2010; 110(5): 51-3.

Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R. et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2003; 31: 579-83.

Pezzotta S, Fante CD, Scudeller L, Cervio M, Antoniazzi ER, Perotti C. Autologous platelet lysate for treatment of refractory ocular GVHD. Bone Marrow Transplant. 2012; 47: 1558-63.

Weng J, He C, Lai P, Luo C, Guo R, Wu S. et al. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. Mol Ther. 2012; 20(12): 2347-54.

Wang Y, Ogawa Y, Dogru M, Kawai M, Tatematsu Y, Uchino M. et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2008; 41: 293-302.

Yoon KC, Jeong IY, Im SK, Park YG, Kim HJ, Choi J. Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease. Bone Marrow Transplant. 2007; 39: 231-5.

Sanz-Marco E, Udaondo P, García-Delpech S, Vazquez A, Diaz-Llopis M. Treatment of Refractory Dry Eye Associated with Graft Versus Host Disease with 0.03% Tacrolimus Eyedrops. J Ocul Pharmacol Ther. 2013; 29(8): 776-83.

Sabti S, Halter JP, Fränkl BCB, Goldblum D. Punctal occlusion is safe and efficient for the treatment of keratoconjunctivitis sicca in patients with ocular GvHD. Bone Marrow Transplant. 2012; 47: 981-4.

Na KS, Kim MS. Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol Ther. 2012; 28(5): 479-83.

Malta JB, Soong HK, Shtein RM, Musch DC, Rhoades W, Sugar A. et al. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea. 2010; 29(12): 1392-6.

Dastjerdi MH, Hamrah M, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009; 28(10): 1091-6.

Takahide K, Parker PM, Wu M, Hwang WYK, Carpenter PA, Moravec C. et al. Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007; 13: 1016-21.

Leite SC, Castro RS, Alves M, Cunha DA, Correa MEP, Silveira LA, et al. Risk factors and characteristics of ocular complications, and efï¬cacy of autologous serum tears after haematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2006: 38: 223-7.

Lelli Júnior GJ, Musch DC, Gupta A, Farjo QA, Nairus TM, Mian SI. Ophthalmic cyclosporine use in ocular GVHD. Cornea. 2006; 25(6): 635-8.

Rao SN, Rao RD. Efï¬cacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease. Cornea. 2006; 25(6): 74-8.

Grob S, Dana R. A pharmacological approach to dry eye syndrome in GVHD. Ophthalmology Times. 2014; 15: 6-8.

Yaguchi S, Ogawa Y, Kamoi1 M, Uchino M, Tatematsu Y, Ban Y. et al. Surgical management of lacrimal punctal cauterization in chronic GVHD-related dry eye with recurrent punctal plug extrusion. Bone Marrow Transplant. 2012; 47(11): 1465-9.

Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea. 2007; 26(10): 1195-9.

Chiang CC, Lin JM, Chen WL, Tsai YY. Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea. 2007; 26(7): 861-3.

Ogawa Y, Okamoto S, Kuwana M, Mori T, Watanabe R, Nakajima T. et al. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea. 2001; 20(4): 430-4.

Alves JS. Olho seco: uma abordagem didática. Rio de Janeiro: E-papers; 2010.

Wan KH, Chen LJ , Young AL. Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis. Ocul Surf. 2015; 13(3): 213-25.

Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev. Mol. Med. 2000; 2: 1-23.

Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000; 47: 119-25.

Nussenblatt RB, Palestine AG. Cyclosporin: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986; 31(3): 159-69.

Song XJ, Li DQ, Farley W, Luo LH, Heuckeroth RO, Milbrandt J. Neurturin-deficient mice develop dry eye and keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2003; 44: 4223-9.

Prabhasawat P, Tseng SC. Frequent association of delayed tear clearance in ocular irritation. Br J Ophthalmol. 1998; 82: 666-75.

Rodriguez-Aller M, Kaufmann B, Guillarme D, Stella C, Furrer P, Rudaz S, et al. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease. European Journal of Pharmaceutics and Biopharmaceutics. 2012; 80: 544-52.

Deveci H, Kobak S. The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren’s syndrome. Int Ophthalmol. 2014; 34:1043-8.

Perez-Rico C, Germain F, Castro-Rebollo M, Moreno-Salgueiro A, Teus MA. Effect of topical 0.05% cyclosporine A on corneal endothelium in patients with dry eye disease. Int J Ophthalmol. 2013; 6(4): 471-4.

Dogru M, Nakamura M, Shimazaki J, Tsubota K. Changing trends in the treatment of dry-eye disease. Expert Opin Investig Drugs. 2013; 22(12): 1581-601.

Harritshøj LH, Nielsen C, Ullum H, Hansen MB, Julian HO. Ready-made allogeneic ABO-specific serum eye drops: production from regular male blood donors, clinical routine, safety and efficacy. Acta Ophthalmol. 2014; 92: 783-6.

Koh S. Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes. Clinical Ophthalmology. 2015; 9: 865-72.

Jung JW, Lee YJ, Yoon SC, Kim T, Kim EK, Seo KY. Long-term Result of Maintenance Treatment With Tacrolimus Ointment in Chronic Ocular Graft-Versus-Host Disease. American Journal of Ophthalmology. 2015; 159(3): 519-27.

Yu FS, Yin J, Xu K, Huang J. Growth factors and corneal epithelial wound healing. Brain Res Bull 2010; 81: 229-35.

Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25: 900-7.

Prockop, DJ, Kota, DJ, Bazhanov, N and Reger, RL (2010). Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J Cell Mol Med. 14 : 2190-99.

Lee MJ, Ko AY, Ko JH, Lee HJ, Kim MK, Wee WR et al. Mesenchymal Stem/Stromal Cells Protect the Ocular Surface by Suppressing Inflammation in an Experimental Dry Eye. Molecular Therapy. 2015; 23(1): 139-46.

Hänisch KT, Neppert B, Geerling G. Gasdurchlässige Sklerallinsen als konservative Therapiealternative bei extremen Hornhautektasien und schwerem Tränenmangel. Ophthalmologe 2005; 102: 387-92.

Shen EP, Hu FR, Lo SC, Chen YM, Sun YC, Lin CT, Chen WL. Comparison of corneal epitheliotrophic capacity among different human blood-derived preparations. Cornea. 2011; 30: 208-14.

Yoon K, Oh J, PARK J, Choi J. Application of umbilical cord serum eyedrops after laser epithelial keratomileusis. 2013; 91: 22-8.

Steven P, Sauerbier L, Siebelmann S, Gehlsen U, Tahmaz V, Wittig S. Therapie der okulären Graft-versus-Host-Erkrankung. Klin Monatsbl Augenheilkd. 2015; 232: 658-63.

Espana EM, Shah S, Santhiago MR, Singh AD. Graft versus host disease: clinical evaluation, diagnosis and management. Graefes Arch Clin Exp Ophthalmol. 2013; 251: 1257-66.

Downloads

Published

2016-04-12

Issue

Vol. 9 (2016)

Section

Ophtalmology

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).

 

 

Most read articles by the same author(s)

1 2 3 > >>